Hemas Holdings Ltd. · CSELK:HHL.N0000
Hemas — Q3 FY24/25 Earnings Presentation
32 slides from Hemas's earnings presentation, 2025
Slide 1: Hemas Holdings PLC Investor Presentation Q3 FY24/25
Hemas Holdings PLC Investor Presentation- Q3 FY24/25
Slide 2: Who We Are
Who We Are Established in 1948, with a purpose of empowering families to live a better tomorrow, Hemas Holdings is one of Sri Lanka’s leading conglomerates listed in the Colombo Stock Exchange with focused interest in Consumer Brands and Healthcare. USD 1948 2003 2007 2013 2018 2022 75 226Mn Years i
Slide 3: Implications of Key Macro Economic Parameters on Hemas
Implications of Key Macro Economic Parameters on Hemas Interest Rates Stable Exchange Rates Global Commodity prices “Prices of key commodities saw an “Continued decline in AWPLR was “The Rupee strengthened further, increasing trend, especially Palm witnessed during the year easing positively impacti
Slide 4: Corporate Governance
Corporate Governance BOM Group CEO Nomination & Governance BOM (Board of Management) Consists of the senior leadership team of 11 members - Heads of our 6 businesses and 5 leaders from Corporate Committee Office. BOM is responsible for formulation and implementation of Group strategic plan and ensur
Slide 5: How Do We Bring Purpose to Life
How Do We Bring Purpose to Life Passion for Obsession Concern for VALUES Driven by Customer for People Innovation Performance Outcome Consumer Driven Centric COMPETENCIES Eliminating Growth-Driven Empower families to aspire for a Purpose Inequality Mindset better tomorrow Our 2030 aspiration Revenue
Slide 6: Group Performance (Annual)
Group Performance (Annual) Revenue (LKR Mn) 5 Year CAGR 13.7% 113,940 121,614 78,831 60,043 64,501 2020 2021 2022 2023 2024 Earnings (LKR Mn) and Earnings Margin EBIT (LKR Mn) and EBIT Margin 5 Year CAGR 12.6% 5 Year CAGR 16.1% 5.4% 6,109 9.6% 9.8% 5.0% 9.4% 8.6% 10,963 4,249 4,269 11,921 5.9% 3,253
Slide 7: Long Range Plan: Key Strategic Pillars
Long Range Plan : Key Strategic Pillars Refreshing High A Enhancing the growth successful efficiencies portfolio spaces turnaround Consumer Brands Pursuing scalable Morison will pivot to Enhance efficiency aims to expand its opportunities across branded and market position presence in the South Asia
Slide 8: Long Range Plan: Key Focus Areas
Long Range Plan : Key Focus Areas ❖ Invest in complementary Hair and ❖ Shift focus to growing the ❖ Continue to strengthen a lean Beauty care, focus on local Morison brand in cardiac, diabetes, business model consumer needs, and drive and complementary medication, household penetration in while enha
Slide 9: Awards and Recognitions
Awards and Recognitions Hemas was recognized as Hemas Hospitals has one of the Top 10 Best been recognized with Corporate Citizens at the the prestigious prestigious Best Business Excellence Corporate Citizen Award at the Asian Sustainability Awards Hospital Management 2024, organized by the Awards
Slide 10: New Product Launches During the Quarter
New Product Launches During the Quarter Personal Care Pharmaceuticals Manufacturing CliniMor tablets (Cilnidipine) 5 mg Vivya Sunscreen Vivya Vitamin C Velvet Body wash 50 ml range of products Naturals range – Avocado and Coconut milk based CliniMor tablets (Cilnidipine) 10 mg Velvet soap Velvet soa
Slide 11: Financial Snapshot
Financial Snapshot EBIT by Sector (Rs. Mn) 9M contribution to the Group 2% 344 41% 57% 280 57% 45% 11% Revenue 233 3,204 272 585 3,103 1,664 1,785 EBIT 1,301 2% 1,271 1,571 1,554 887 952 Consumer Healthcare Mobility (157) (54) (466) (256) (397) FY22 Q3 FY23 Q3 FY24 Q3 FY25 Q3 FY25 Q2 9M Performance
Slide 12: Sector Performance Summary – Q3 FY 2024-25
Sector Performance Summary – Q3 FY 2024-25 Revenue Walk (LKR Mn) EBIT Walk (LKR Mn) 92,000 10,000 320 67 9,887 (42) 90,174 213 754 90,000 (23) 9,500 (642) 88,000 87,623 9,000 (2,098) 8,788 86,000 8,500 84,000 8,000 82,000 7,500 80,000 7,000 Q3 FY 24 Mobility Other Healthcare Consumer Q3 FY 25 Q3 FY
Slide 13: Continuing Operation EPS – Q3 FY 2024-25
Continuing Operation EPS – Q3 FY 2024-25 EPS Walk (LKR Per Share) 12.00 10.00 1.84 0.06 0.24 (0.08) 9.50 1.74 11.00 9.18 9.00 (0.45) 10.00 2.13 8.50 9.18 9.00 (2.31) 8.00 7.60 8.00 7.50 7.60 7.00 7.00 6.50 6.00 6.00 5.00 5.50 4.00 5.00 Q3 FY 24 Net fin. cost EBIT NCI Income tax Q3 FY 25 Q3 FY 24 Hea
Slide 14: Capital Employed – FY 2024-25
Capital Employed – FY 2024-25 Sector Efficiency Capital Employed, ROCE, and EBIT by Sector 60% Mobility LKR 1,322.9 Mn Consumer 50% 48.5% LKR 7,166.2 Mn 40% 35.4% Healthcare 30% LKR 6,129.3 Mn Group ROCE : 24.3 % ROCE (%) 20% 21.5% 10% 0% 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 -10% -11.1%
Slide 15: Consumer Brands
Consumer Brands ❖ Home and Personal Care - Sri Lanka ❖ Home and Personal Care - International ❖ Learning Segment
Slide 16: Consumer Brands
Consumer Brands Contribution to Group Sector Performance – 9M FY 2024-25 41% Revenue % Revenue (LKR Mn) Key Highlights 9M FY25 4.0% 42% (YoY) • The appreciation of the Rupee and the 9M FY24 decline in commodity prices have intensified competition within the industry, with several players offering a
Slide 17: Home and Personal Care – Sri Lanka
Home and Personal Care – Sri Lanka 8 Key categories with market Purpose-driven brands touching the lives of the Sri Lankan consumer leading positions Extensions to the Portfolio Inclusive Strong roots Parenting Stronger Make a Celebrating Enabling Both parents together Positive Difference & Nurturin
Slide 18: Home and Personal Care – International
Home and Personal Care – International Locally led and localised in Bangladesh Reach in Bangladesh 2 Geographies Bangladesh & West Bengal • All products are exclusively designed for Bangladesh. Rural penetration by • Extensive product portfolio with multiple value 19.3% Hemas Key categories 3• Value
Slide 19: Home and Personal Care – Sri Lanka and International
Home and Personal Care – Sri Lanka and International Sri Lanka International Revenue Revenue Revenue (LKR Mn) • The personal care segment experienced volume-led growth • Revenue was impacted by by rising inflation and increased price sensitivity, which have led many • The Home care segment saw a dec
Slide 20: Learning Segment
Learning Segment Revenue • In response heightened competition from 7 Key categories new entrants offering products at lower price points and varying quality, several Revenue (LKR Mn) initiatives were launched to increase 3.6 % awareness and create a unique and innovative point of difference, such as
Slide 21: Healthcare Sector
Healthcare Sector ❖ Pharmaceutical Import, Marketing and Distribution ❖ Pharmaceutical Manufacturing ❖ Hospitals
Slide 22: Healthcare
Healthcare Contribution to Group Sector Performance – 9M FY 2024-25 57% Revenue % Revenue (LKR Mn) Key Highlights 9M FY25 8.7 % 9M FY24 56% • The Healthcare industry has been (YoY) gaining momentum and recovering from the downturn 18,237 16,130 17,442 16,657 experienced during the economic EBITDA %
Slide 23: Pharmaceutical Import, Marketing, Distribution and Manufacturing
Pharmaceutical Import, Marketing, Distribution and Pharmaceutical Manufacturing Revenue Revenue (LKR Mn) • The Distribution business continues to hold its market-leading position this quarter • Pharmaceutical Manufacturing business of the Group continued to expand the Morison branded portfolio with
Slide 24: Hospitals
Hospitals Revenue Revenue (LKR Mn) • While outpatient revenue has seen a steady increase, inpatient revenue experienced a decline 190+ Beds due to lower admissions, which was a trend observed across the market. 4.9 % (YoY) +51% Hospital occupancy Profitability • GP & EBITDA margins improved owing to
Slide 25: Mobility Sector
Mobility Sector ❖Maritime ❖Aviation
Slide 26: Mobility
Mobility Contribution to Group Sector Performance – 9M FY 2024-25 2% Revenue % Revenue (LKR Mn) Key Highlights 12.6% 9M FY25 1% (YoY) 9M FY24 • The Maritime sector witnessed an increase in both freight rates and volumes in the import and export 519 operations compared to the 476 477 previous year. E
Slide 27: Environmental Agenda 2030
Environmental Agenda 2030 Encouraging responsible Protecting plastic consumption Sri Lankan endemism 1.2 Million+ Kgs 15 Critically endangered Collection of plastic endemic species to date
Slide 28: Social Impact: Focus Areas
Social Impact : Focus Areas Q3 FY 25: 49,000+ Families Empowered Creating Equal Supporting Health and Empowering Vulnerable Opportunities for Learning Well-being Communities • Empowering women • Creating quality • Providing expert advise with entrepreneurship, educational and guidance to knowledge-b
Slide 29: Social Impact: 49,000+ Families Empowered
Social Impact : 49,000+ Families Empowered TACKLING PERIOD POVERTY PROVIDING WIGS TO CANCER PATIENTS CREATING A SAFER WORLD CREATING EQUAL LEARNING OPPURTUNITY 10,827 350 2,307 22,795 Women and Girls Women Children, Teachers and Parents Families CREATING QUALITY LEARNING ENSURING NO CHILD IS LEFT BE
Slide 30: Sustainability Performance – Q1 24–25 vs Q1 23-24
Sustainability Performance– Q1 24–25 VS Q1 23-24 Values of Fines for Non-Compliance Carbon Footprint (per Rs. Mn Revenue) 0.9MT with Laws and Regulations in the NONE Social Economic Area Water Consumption Total Work-Related Injury Rate (per Rs. Mn Revenue) 15.6% 1.3 m3 (per 100 employee) 200% 0.3 Wa
Slide 31: Key Priorities
Key Priorities Focus on Personal care, Beauty and wellness with a drive for premiumisation and exploring underpenetrated Markets Corporate Priorities Strengthening value prepositions to grow market share Accelerating the M&A opportunities Accelerate exports and international expansion Consumer Drivi
Slide 32: Disclaimer
Disclaimer The material in this presentation has been prepared by Hemas Holdings PLC (“Hemas”) and is general background information about Hemas’ activities current as at the date of this presentation. This information is given in summary form and does not purport to be complete. Information in this